ClinicalTrials.gg
CompletedNCT03898908EBRAIN-MELUpdated May 21, 2025Results posted

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

A Phase 2 interventional study of encorafenib and binimetinib in Metastatic Melanoma and Brain Metastases, sponsored by Grupo Español Multidisciplinar de Melanoma. Completed at 21 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Grupo Español Multidisciplinar de Melanoma · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing encorafenib in Melanoma — 4 open to participants now, 8 under way, 2 of them phase 3. encorafenib · Melanoma.

Enrollment
12th of 27
48 · median 35
Started
2019
with 1 other
Phase 2
14 of 27
3 open now
Registered
16th of 27
by date
Lead sponsor
1 of 27
Grupo Español Multidisciplinar de Melanoma

Among the 27 studies testing encorafenib in Melanoma, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is one of 14 in phase 2, and was the 16th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 27 studies testing encorafenib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing encorafenib in Melanoma, or all of them as a file.
02

Study summary

Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.

03

Conditions studied

  • Metastatic Melanoma
  • Brain Metastases

Keywords

  • metastases
  • melanoma
  • encorafenib
  • binimetinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written of approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial activities.
  • confirmed diagnosis of unresectable cutaneous melanoma, or unknown primary melanoma with one or more with a diameter of 10 to 50 mm, measured by contrast enhanced MRI.
  • Presence of a BRAF V600E or V600K mutation, or both, in their tumour tissue.
  • Barthel Index of Activities of Daily Living > 10.
  • Subjects aged ≥ 18 years.
  • 0-1 in asymptomatic patients (cohort 1), 0-2 in symptomatic patients (cohort 2).
  • Adequate haematological function ( ≥ 9 g/dL, may have been transfused; count ≥ 100 × 109/L; (ANC) ≥ 1.5 × 109/L.)
  • Adequate hepatic function defined by a total level ≤ 2.0 × the upper limit of normality () and and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).
  • Serum Creatinine ≤ 2.0 x ULN or estimated ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
  • Evidence of at least one as detected by radiological or photographic methods according to guidelines based on (RECIST) version 1.1.
  • Naïve untreated patients or patients who have progressed on or after prior immunotherapy for unresectable locally advanced or metastatic melanoma, but it must have ended at least 6 weeks prior to randomization; prior therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), BRAF or MEK inhibitors can be used in the adjuvant setting, providing the relapse does not occur during the adjuvant treatment or within 12 months after the end of it, and providing the adjuvant treatment with targeted therapy did not cause in the patient any grade 3-4 toxicity not including medically serious and reversible/controlled toxicities (ex: GGT elevation, CPK elevation, vomiting).
  • or anticonvulsants are allowed if clinically needed and are not being administered in an increasing dose.
  • Female subjects must either be of non- (ie, by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
  • Normal functioning of daily living activities.
  • Willingness and ability to attend scheduled visits, follow the treatment schedule and undergo clinical tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Uveal or mucosal melanoma.
  • History of , with the exception that they are only seen in brain MRI and the patient has 0-1 and no neurological symptoms (except for cohort 2, where symptomatic patients will be allowed if ECOG is 0-2).
  • Another cancer in the last five years, except for in situ carcinoma of the cervix or squamous cell carcinoma of the skin adequately treated or limited basal cell skin cancer adequately controlled.
  • History of or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or history of retinal degenerative disease (RDD).
  • Any previous systemic chemotherapy treatment, extensive brain radiotherapy, targeted therapy for locally advanced unresectable or melanoma; Immunotherapy treatment is allowed but must have ended at least 6 weeks prior to randomization.
  • History of Gilbert's syndrome.
  • Previous treatment with a BRAF or MEK inhibitor in metastatic setting. This treatment will be allowed in the setting (see above). Previous treatments with immunotherapy will be allowed in both the metastatic and adjuvant setting.
  • Known positive serology for , or an active or infection, or both.
  • Impaired cardiovascular function or cardiovascular diseases "Clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke (\< 6 months prior to enrolment), myocardial infarction (\< 6 months prior to enrolment), unstable angina, congestive heart failure (≥ Classification Class II), a \< 50% evaluated by MUGA or echocardiography, or serious cardiac arrhythmia requiring medication or a triplicate average baseline > 500 ms."
  • Uncontrolled arterial hypertension despite medical treatment.
  • Moderate ( Class B) or severe (Child Pugh Class C) hepatic impairment.
  • Impairment of gastrointestinal function.
  • Neuromuscular disorders associated with high concentrations of creatine kinase.
  • Pregnant or nursing (lactating) women.
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give , comply with the study protocol or complete the study.
  • Known to encorafenib, binimetinib or their components.
  • Persisting toxicity related to prior therapy of Grade >1 v 4.03; however, alopecia and sensory neuropathy Grade ≤ 2 is acceptable.
  • Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ highly effective from screening to 180 days after the last dose of study treatment.
  • Known alcohol or drug abuse.
  • Inability to swallow tablets or capsules.
  • Total lactase deficiency or glucose-galactose malabsorption.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    COMBO450

    Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death.

    Drug: encorafenib · Drug: binimetinib · Radiation: Whole brain radiation therapy · Radiation: Radiosurgery/stereotactic radiosurgery

Interventions

  • Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment. If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death.

    Also known as: Braftovi

  • Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.

    Also known as: Mektovi

  • RadiationWhole brain radiation therapy

    The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks.

  • RadiationRadiosurgery/stereotactic radiosurgery

    Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures. Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy. For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week.

06

What researchers measure

Primary outcomes

  1. Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset

    iORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment according to modified RECIST 1.1. Modified RECIST 1.1 consists of: Up to 5 intracranial lesions could be selected as target lesions Target lesions might have a longest diameter ≥ 5 mm when evaluated by contrast-enhanced MRI This endpoint was also independently reported in patients with symptomatic and asymptomatic brain metastasis.

    Time frame: 24 months after start of treatment

Secondary outcomes

  1. Duration of Intracranial Response

    Calculated as the time from the date of first documented CR or PR to the first documented intracranial progression or death due to underlying cancer accoridng to modified RECIST 1.1, in patients with documented intracranial CR or PR before local treatment.

    Time frame: Throughout the study period, up to approximately 24 months

  2. Intracranial Progression-free Survival (iPFS) by RECIST 1.1

    Defined as the time from the date of inclusion to the date of the first documented intracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (modified RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion.

    Time frame: Throughout the study period, up to approximately 24 months

  3. Extracranial Progression-free Survival (ePFS) in Both Cohorts

    Defined as the time from the date of inclusion to the date of the first documented extracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion.

    Time frame: Throughout the study period, up to approximately 24 months

  4. Intracranial Progression-free Rates

    Proportion of patients free of intracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method

    Time frame: at 6 months (week 24), 12 months (week 48) and 24-month (week 96)

  5. Overall Survival

    Calculated as the time from date of inclusion to date of death due to any cause.

    Time frame: Throughout the study period, up to approximately 24 months

  6. Overall Survival Rates

    Proportion of of patients alive at 6 months, 12 month and 24-month considering date of inclusion estimated using Kaplan-Meier. Patients alive at the moment of the analysis were censored on the date of their last follow-up.

    Time frame: at 6 months, 12 month and 24-month

  7. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

    Number of patients experiencing treatment related adverse events. These events were graded accrding to CTCAE, a scale that ranges from 0 (less intense; no event) to 5 (death) . Here we report the number of patients experiencing any grade toxicities and the number of patients experiencing high grade (grade 3-5) toxicities.

    Time frame: Throughout the study period, up to approximately 24 months

  8. Change on Quality of Life at Week 8 in Both Cohorts Based on the EORTC QLQ 30 Scale

    The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance

    Time frame: 8 weeks

  9. Change on Quality of Life at Week 24 in Both Cohorts Based on the EORTC QLQ 30 Scale

    The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance

    Time frame: 24 weeks

  10. Extracranial Progression-free Rates

    Proportion of patients free of extracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method

    Time frame: at 6 months (week 24), 12 months (week 48) and 24-month (week 96)

07

Results

Posted May 13, 2025

Participant flow

the initial sample size was set at 48 patients, to ensure obtaining 38 evaluable patients. The cohort of symptomatic patients was exploratory and no formal sample calculation was performed, anticipating the inclusion of up to 15 patients.The trial was amended and patients were included irrespective of symptomatology.

Participant flow — Overall Study
MilestoneCOMBO450
Started48
Completed48
Not completed0

Outcome measures

PrimaryIntracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset

iORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment according to modified RECIST 1.1. Modified RECIST 1.1 consists of: Up to 5 intracranial lesions could be selected as target lesions Target lesions might have a longest diameter ≥ 5 mm when evaluated by contrast-enhanced MRI This endpoint was also independently reported in patients with symptomatic and asymptomatic brain metastasis.

Time frame:
24 months after start of treatment
Reported as:
Count of participants · Participants
Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset
ParticipantsCOMBO450
Full analysis set — Patients with intracranial response34
Full analysis set — Patients with NO intracranial response13
Full analysis set — Not evaluable1
Asymptomatic brain metastasis — Patients with intracranial response20
Asymptomatic brain metastasis — Patients with NO intracranial response5
Asymptomatic brain metastasis — Not evaluable0
Symptomatic brain metastasis — Patients with intracranial response14
Symptomatic brain metastasis — Patients with NO intracranial response8
Symptomatic brain metastasis — Not evaluable1
SecondaryDuration of Intracranial Response

Calculated as the time from the date of first documented CR or PR to the first documented intracranial progression or death due to underlying cancer accoridng to modified RECIST 1.1, in patients with documented intracranial CR or PR before local treatment.

Time frame:
Throughout the study period, up to approximately 24 months
Reported as:
Median · months
Duration of Intracranial Response
monthsCOMBO450
Duration of Intracranial Response5.6 (3.6 to 7.5)
SecondaryIntracranial Progression-free Survival (iPFS) by RECIST 1.1

Defined as the time from the date of inclusion to the date of the first documented intracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (modified RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion.

Time frame:
Throughout the study period, up to approximately 24 months
Reported as:
Median · months
Intracranial Progression-free Survival (iPFS) by RECIST 1.1
monthsCOMBO450
Intracranial Progression-free Survival (iPFS) by RECIST 1.18.5 (6.4 to 11.8)
SecondaryExtracranial Progression-free Survival (ePFS) in Both Cohorts

Defined as the time from the date of inclusion to the date of the first documented extracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion.

Time frame:
Throughout the study period, up to approximately 24 months
Reported as:
Median · months
Extracranial Progression-free Survival (ePFS) in Both Cohorts
monthsCOMBO450
Extracranial Progression-free Survival (ePFS) in Both Cohorts7.7 (6.1 to 11.8)
SecondaryIntracranial Progression-free Rates

Proportion of patients free of intracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method

Time frame:
at 6 months (week 24), 12 months (week 48) and 24-month (week 96)
Reported as:
Number · Percentage of patients free of PD
Intracranial Progression-free Rates
Percentage of patients free of PDCOMBO450
6 months66.8 (54.4 to 82.1)
12 months29.5 (18.2 to 47.6)
24 months5.5 (0.9 to 32)
SecondaryOverall Survival

Calculated as the time from date of inclusion to date of death due to any cause.

Time frame:
Throughout the study period, up to approximately 24 months
Reported as:
Median · months
Overall Survival
monthsCOMBO450
Overall Survival15.9 (10.7 to 21.4)
SecondaryOverall Survival Rates

Proportion of of patients alive at 6 months, 12 month and 24-month considering date of inclusion estimated using Kaplan-Meier. Patients alive at the moment of the analysis were censored on the date of their last follow-up.

Time frame:
at 6 months, 12 month and 24-month
Reported as:
Number · Percentage of patients alive
Overall Survival Rates
Percentage of patients aliveCOMBO450
6 months91.6 (84.1 to 99.8)
12 months59.2 (46.2 to 76)
24 months15.5 (6.7 to 35.8)
SecondaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Number of patients experiencing treatment related adverse events. These events were graded accrding to CTCAE, a scale that ranges from 0 (less intense; no event) to 5 (death) . Here we report the number of patients experiencing any grade toxicities and the number of patients experiencing high grade (grade 3-5) toxicities.

Time frame:
Throughout the study period, up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
ParticipantsCOMBO450
Any grade toxicities — Experienced Toxicity40
Any grade toxicities — Do NOT experienced toxicity8
Grade 3-5 toxicities — Experienced Toxicity12
Grade 3-5 toxicities — Do NOT experienced toxicity36
SecondaryChange on Quality of Life at Week 8 in Both Cohorts Based on the EORTC QLQ 30 Scale

The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance

Time frame:
8 weeks
Reported as:
Median · Score
Change on Quality of Life at Week 8 in Both Cohorts Based on the EORTC QLQ 30 Scale
ScoreCOMBO450
Week 885.5 (48.6 to 99.4)
Baseline78.4 (29.3 to 98.7)
Statistical analysis
  • COMBO450 · Wilcoxon (Mann-Whitney) · p = 0.015 (pValues below 0.05 are considered statistically significant)
SecondaryChange on Quality of Life at Week 24 in Both Cohorts Based on the EORTC QLQ 30 Scale

The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance

Time frame:
24 weeks
Reported as:
Median · Score
Change on Quality of Life at Week 24 in Both Cohorts Based on the EORTC QLQ 30 Scale
ScoreCOMBO450
Week 2474.9 (47.3 to 97.9)
Baseline78.4 (29.3 to 98.7)
Statistical analysis
  • COMBO450 · Wilcoxon (Mann-Whitney) · p = 0.754 (pValues below 0.05 are considered statistically significant)
SecondaryExtracranial Progression-free Rates

Proportion of patients free of extracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method

Time frame:
at 6 months (week 24), 12 months (week 48) and 24-month (week 96)
Reported as:
Number · Percentage of patients free of PD
Extracranial Progression-free Rates
Percentage of patients free of PDCOMBO450
6 months64.1 (51.4 to 79.9)
12 months31.2 (19.6 to 49.6)
24 months5.8 (1 to 33.8)

Adverse events

Collected over Throughout the study period, up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COMBO45033/48 (68.8%)22/48 (45.8%)48/48 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventCOMBO450
SeizureNervous system disorders3/48
AnemiaBlood and lymphatic system disorders2/48
DiarrheaGastrointestinal disorders2/48
HeadacheNervous system disorders2/48
AnaphylaxisImmune system disorders1/48
Creatinine increasedInvestigations1/48
VomitingGastrointestinal disorders1/48
Upper gastrointestinal hemorrhageGastrointestinal disorders1/48
Pulmonary thromboembolismRespiratory, thoracic and mediastinal disorders1/48
Right pleural empyema by streptococcus constellatusRespiratory, thoracic and mediastinal disorders1/48
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCOMBO450
DiarrheaGastrointestinal disorders13/48
FatigueGeneral disorders12/48
NauseaGastrointestinal disorders11/48
Alanine aminotransferase increasedInvestigations9/48
AnemiaBlood and lymphatic system disorders8/48
Aspartate aminotransferase increasedInvestigations8/48
GGT increasedInvestigations8/48
FeverGeneral disorders7/48
Other not specifiedSkin and subcutaneous tissue disorders7/48
Other not specifiedInvestigations6/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)COMBO450
Median54 (18 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)COMBO450
Female24
Male24
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)COMBO450
Region of Enrollment
Region of Enrollment(participants)COMBO450
Spain48
Eastern cooperative oncology group (ECOG) performance status (PS) at baseline
Eastern cooperative oncology group (ECOG) performance status (PS) at baseline(Participants)COMBO450
Score 026
Score 120
Score 22
Barthel Index
Barthel Index(Participants)COMBO450
Total dependent (0-4)3
Severe dependent (5-12)4
Moderate dependent (13-18)6
Slight dependent (19-20)33
NA2
BRAF genotype
BRAF genotype(Participants)COMBO450
V600E — Mutated41
V600E — Not mutated7
V600K — Mutated11
V600K — Not mutated37
V600R — Mutated6
V600R — Not mutated42
V600 other — Mutated25
V600 other — Not mutated23
Brain symptoms
Brain symptoms(Participants)COMBO450
Asymptomatic25
Symptomatic23

8 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Hospital Universitario Son Espases
    Palma De Mallorca, Baleares, Spain
  • Institut Català d'Oncología Hospitalet
    Barcelona, Barcelona, Spain 08908, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria, Spain
  • Hospital Universitario Quirón Dexeus
    Barcelona, Cataluña, Spain
  • Complejo Hospitalario Universitario Insular de Canarias
    Las Palmas de Gran Canaria, Las Palmas, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, Spain
  • Hospital Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • H. U. Gregorio Marañón
    Madrid, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Spain
  • Clínica Universidad de Navarra
    Pamplona, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, Spain
  • Hospital General Universitario de Valencia
    Valencia, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • Hospital Miguel Servet
    Zaragoza, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2022, 38 months.

Results were first posted in May 2025, 2 years 7 months after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 38 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 2, 2019
StartActual
Jul 18, 2019
Primary completionActual
Oct 10, 2022
CompletionActual
Jul 31, 2023
Results first posted
May 13, 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03898908
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Collaborators
Pierre Fabre Medicament, MFAR
Responsible party
Sponsor
First posted
Apr 2, 2019
Start date
Jul 18, 2019
Primary completion
Oct 10, 2022
Completion
Jul 31, 2023
Results posted
May 13, 2025
Last update
May 21, 2025

Study contacts

Iván Márquez Rodaz, M.D.
study chair · Hospital General Universitario Gregorio Marañón
Alfonso Berrocal Jaime, M.D.
study chair · Hospital Universitario General de Valencia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Binimetinib

Start the discussion